Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
10.69
0.00 (0.00%)
At close: Nov 14, 2025, 4:00 PM EST
10.66
-0.03 (-0.27%)
After-hours: Nov 14, 2025, 7:10 PM EST
Evoke Pharma Revenue
Evoke Pharma had revenue of $4.28M in the quarter ending September 30, 2025, with 61.40% growth. This brings the company's revenue in the last twelve months to $14.42M, up 67.40% year-over-year. In the year 2024, Evoke Pharma had annual revenue of $10.25M with 97.84% growth.
Revenue (ttm)
$14.42M
Revenue Growth
+67.40%
P/S Ratio
2.06
Revenue / Employee
$4,808,217
Employees
3
Market Cap
22.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.25M | 5.07M | 97.84% |
| Dec 31, 2023 | 5.18M | 2.67M | 106.51% |
| Dec 31, 2022 | 2.51M | 890.57K | 55.04% |
| Dec 31, 2021 | 1.62M | 1.60M | 6,929.00% |
| Dec 31, 2020 | 23.02K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVOK News
- 12 days ago - MAI Capital Management Announces Expanded Office of Managing Partners Appointments Following Strategic Acquisition of Evoke Advisors - Business Wire
- 6 weeks ago - Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year - Business Wire
- 2 months ago - MAI Capital Management Announces Strategic Partnership with Evoke Advisors - Business Wire
- 2 months ago - Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship - GlobeNewsWire
- 3 months ago - Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book - GlobeNewsWire
- 3 months ago - Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 - GlobeNewsWire
- 4 months ago - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 - GlobeNewsWire
- 6 months ago - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire